Get the Stockscreener App
11.72
3.93%
-0.48
After Hours:
13.70
1.98
+16.89%
Promis Neurosciences Inc stock is traded at $11.72, with a volume of 95,211.
It is down -3.93% in the last 24 hours and up +11.30% over the past month.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
See More
Previous Close:
$12.20
Open:
$12.59
24h Volume:
95,211
Relative Volume:
1.85
Market Cap:
$105.10M
Revenue:
-
Net Income/Loss:
$-40.62M
P/E Ratio:
-0.6039
EPS:
-19.4076
Net Cash Flow:
$-35.63M
1W Performance:
-22.26%
1M Performance:
+11.30%
6M Performance:
+9.94%
1Y Performance:
-52.48%
1-Day Range:
$11.25
$12.59
1-Week Range:
$11.25
$15.52
52-Week Range:
$6.27
$27.40
Promis Neurosciences Inc Stock (PMN) Company Profile
Name
Promis Neurosciences Inc
Sector
Industry
Phone
416-847-6898
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
11.72 | 109.41M | 0 | -40.62M | -35.63M | -19.41 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Promis Neurosciences Inc Stock (PMN) Latest News
ProMIS Neurosciences Inc (PMN) Income Statement - TradingKey
ProMIS Neurosciences to present interim Alzheimer’s trial data on PMN310 - TipRanks
ProMIS to host webinar on Alzheimer’s trial interim data - Investing.com
Two Alzheimer’s researchers join ProMIS webinar on blinded trial data - Stock Titan
PMN Initiated Coverage by Chardan Capital -- Rating Set to Buy - GuruFocus
PMN|ProMIS Neurosciences Inc|Price:11.655|Chg%:-0.545 - TradingKey
ProMIS Neurosciences Inc (PMN) Balance Sheet - TradingKey
Chardan initiates ProMIS Neurosciences stock with buy rating By Investing.com - Investing.com Canada
PMN|ProMIS Neurosciences Inc|Price:12.200|Chg%:-0.410 - TradingKey
ProMIS Neurosciences Inc (PMN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ProMIS Neurosciences Inc (PMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProMIS Neurosciences Inc (PMN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ProMIS Neurosciences Inc (PMN) Institutional Confidence - TradingKey
ProMIS Neurosciences Inc (PMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProMIS Neurosciences Inc (PMN) Cash Flow - TradingKey
ProMIS Neurosciences Inc. Revenue Breakdown – NASDAQ:PMN - TradingView
ProMIS Neurosciences Inc (PMN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Guggenheim Sticks to Their Buy Rating for ProMIS Neurosciences (PMN) - The Globe and Mail
H.C. Wainwright Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
ProMIS reports PMN310 oligomer reduction at 29 days - grafa.com
ProMIS Neurosciences (PMN) Reports Dose-Dependent Reduction in A - GuruFocus
One Dose of PMN310 Reduced Toxic Amyloid Oligomers in Spinal Fluid - Stock Titan
ProMIS Neurosciences Reports Dose-Dependent Reduction of Amyloid-Beta Oligomers for PMN310 in Healthy Volunteers - Quiver Quantitative
ProMIS Neurosciences Reports First Human Evidence of - GlobeNewswire
ProMIS Neurosciences Inc. Financial Statements – NASDAQ:PMN - TradingView
PMN Initiated Coverage by Roth Capital -- Rating Set to Buy - GuruFocus
ProMIS Neurosciences (PMN) Slips Marginally, Holds Near Key SupportTick Index - dars.gov.et
PMN Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ove - GuruFocus
Wall Street Analysts See a 230.23% Upside in Promis Neurosciences (PMN): Can the Stock Really Move This High? - Yahoo Finance
ProMIS Neurosciences Inc (PMN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enterprise value to revenue forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
ProMIS Neurosciences Inc. Actuals & Estimates (NASDAQ:PMN) - TradingView
PMN Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
Price to sales forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
Price to book forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
PMN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
H.C. Wainwright reiterates ProMIS Neurosciences stock rating at buy By Investing.com - Investing.com Nigeria
PMN Q1 2026 Earnings: Narrower-Than-Expected Loss as Preclinical Pipeline AdvancesEBITDA Estimate Trend - DonanımHaber
ProMIS Neurosciences Inc (PMN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PMN Q1 2026 Earnings: EPS Beat Surprises as ProMIS Advances PipelinePretax Income Report - newsline.com
PMN Q1 2026 Earnings: Narrowing Losses Amidst Clinical ProgressProfit Inflection Point - newsline.com
ProMIS Neurosciences (PMN) Dips 3.54% as Biotech Stock Tests Key Support ZonePrice Action Signals - newsline.com
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy - Yahoo Finance
Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a Bet - Yahoo Finance
ProMIS Neurosciences Inc. (PMN) Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Amid Pipeline AdvancesAnalyst Drop Coverage - newsline.com
H.C. Wainwright reiterates Buy on ProMIS Neurosciences stock By Investing.com - Investing.com Canada
Promis Neurosciences Inc Stock (PMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):